Elevated Bilirubin-to-Albumin Ratio as a Predictor of Mortality in Liver Diseases
Main Article Content
Abstract
Objective;
The objective of this study is to evaluate the prognostic accuracy of the bilirubin-to-albumin ratio for predicting mortality in patients with chronic or acute liver disease presenting with acute liver failure.
Methodology:
This was a multicenter descriptive cross-sectional study which was performed in the Department of General Medicine, Hayatabad Medical Complex, Department of Pediatrics, Lady Reading Hospital, Peshawar, and Department of Medicine, District Headquarters Teaching Hospital, Haripur, Pakistan. The study duration was about 3 months extending from 10th August 2024 to 22nd December 2024. We consecutively collected 69 patients of both genders with chronic or acute liver diseases presenting with liver failure as evidenced by hepatic encephalopathy, increased prothrombin time and INR. The patients were recruited from the wards and ICUs of the respective hospitals. The underlying etiology of liver disease was identified, and related blood tests including the serum bilirubin and albumen, were performed within the first 24 hours of admission at the main laboratories of the respective hospitals. Bilirubin-to-albumin (B/A) ratio was calculated by dividing the total bilirubin (mg/dl) by the serum albumin (gm/dl) at the time of admission. The normal range of the bilirubin albumen ratio (B/A) is 0.01–0.2, while levels above 0.7 were considered significant and classified as elevated in this study. All patients were monitored throughout their hospital stay and for three months post-discharge. Mortality within this follow-up period was assessed.
Results;
The total number of patients was 69 and the age range was from 1 to 62 years with mean age of 43.130±4.90 years and mean duration of liver disease was 19.985±4.55 months. An elevated bilirubin/albumin (B/A) ratio was diagnosed in 29(42%) and the total mortality was seen in 33(47.8%). Bilirubin/Albumin (B/A) ratio showed sensitivity of 66.7%, specificity 80.5%, diagnostic accuracy 74%, with positive predictive value 75.9% and negative predictive value of 72.5%.
Conclusion;
Results from the present study showed that a normal or near normal Bilirubin/Albumin (B/A) ratio determined on admission predicts good prognosis regarding the survival of patients with acute liver failure. Based on our preliminary data, a future study with a large number of patients would be required to adequately power a multivariate analysis.
Article Details
Work published in JPMI is licensed under a
Creative Commons Attribution-NonCommercial 2.0 Generic License.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
References
Kalakonda A, Jenkins BA, John S. Physiology, Bilirubin. PMID: 29261920.
Ngashangva L, Bachu V, Goswami P. Development of new methods for determination of bilirubin. Journal of pharmaceutical and biomedical analysis. 2019 Jan 5; 162:272-85. Doi. 10.1016/j.jpba.2018.09.034
Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. Journal of hepatology. 2019 Jan 1;70(1):151-71.
Majid B, Khan R, Junaid Z, Khurshid O, Rehman SH, Jaffri SN, Zaidi B, Zehra J, Batool S, Altaf S, Jatoi A. Assessment of knowledge about the risk Factors of chronic liver disease in patients admitted in Civil Hospital Karachi. Cureus. 2019 Oct;11(10).
de La Rica R, Borges M, Aranda M, Del Castillo A, Socias A, Payeras A, Rialp G, Socias L, Masmiquel L, Gonzalez-Freire M. Low albumin levels are associated with poorer outcomes in a case series of COVID-19 patients in Spain: a retrospective cohort study. Microorganisms. 2020 Jul 24;8(8):1106.
DARBANDSAR MP, Heydari K, Hatamabadi H, Kashani P, JAMALI DY. Acute Physiology and Chronic Health Evaluation (APACHE) III Score com-pared to Trauma-Injury Severity Score (TRISS) in Predicting Mortality of Trauma Patients.
Carvalho JR, Machado MV. New insights about albumin and liver disease. Annals of hepatology. 2018 Jul 1;17(4):547-60.
Chakrabarti U, Thakur MB. Albumin bilirubin (ALBI) score: a new and simple model to predict mortality in patients of acute on chronic liver failure. The Journal of the Association of Physicians of India. 2020 Jan 1;68(1):91
Chen B, Lin S. Albumin-bilirubin (ALBI) score at admission predicts possible outcomes in patients with acute-on-chronic liver failure. Medicine. 2017 Jun 1;96(24):e7142.
Ardakani SB, Dana VG, Ziaee V, Ashtiani MT, Djavid GE, Alijani M. Bilirubin/albumin ratio for predicting acute bilirubin-induced neurologic dysfunction. Iranian Journal of Pediatrics. 2011 Mar;21(1):28.
Tsoris A, Marlar CA. Use of the Child Pugh score in liver disease.
Goudsmit BF, Putter H, Van Hoek B. The model for end-stage liver disease 3.0: an update without proven accuracy. Gastroenterology. 2022 May 1;162(6):1781-2.
Freeman Jr RB, Wiesner RH, Harper A, McDiarmid SV, Lake J, Edwards E, Merion R, Wolfe R, Turcotte J, Teperman L. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transplantation. 2002 Sep 1;8(9):851-8.
Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O'Beirne J, Fox R, Skowronska A, Palmer D, Yeo W. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade. Journal of Clinical Oncology. 2015 Feb 20;33(6):550-8.
Pinato DJ, Sharma R, Allara E, Yen C, Arizumi T, Kubota K, Bettinger D, Jang JW, Smirne C, Kim YW, Kudo M. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. Journal of hepatology. 2017 Feb 1;66(2):338-46.
Toyoda H, Lai P, O'Beirne J, Chong CC, Berhane S, Reeves H, Manas D, Fox RP, Yeo W, Mo F, Chan AW. Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. British journal of cancer. 2016 Mar;114(7):744-50.
Ma XL, Zhou JY, Gao XH, Tian L, Wu J, Zhang CY, Zhou Y, Dai Q, Wang BL, Pan BS, Yang XR. Application of the albumin-bilirubin grade for predicting prognosis after curative resection of patients with early-stage hepatocellular carcinoma. Clinica chimica acta. 2016 Nov 1;462:15-22.
Ogasawara S, Chiba T, Ooka Y, et al. Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma. Invest New Drugs 2015; 33:1257–62.
